All In Biotech

Drug Trial Radar · NCT07548606

A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)

A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effects of Multiple Doses of Itraconazole on the Single-Dose Pharmacokinetics of MK-5684 in Healthy Adult Male Participants

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

May 11, 2026

Primary completion

Jun 1, 2026

Study completion Jun 18, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to opevesostat in the body when it is given with and without another medicine called itraconazole.

Conditions

  • Healthy

Interventions

  • OpevesostatDrug

    Administered via oral film-coated tablet

  • PrednisoneDrug

    Administered via oral tablet

  • Fludrocortisone acetateDrug

    Administered via oral tablet

  • ItraconazoleDrug

    Administered via oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration versus time curve from 0 to infinity after single dosing (AUC0-inf) of opevesostatTime frame: Predose, and at designated timepoints up to 144 hours post-dose
  2. Area under the concentration versus time curve from 0 to last quantifiable sample (AUC0-last) of opevesostatTime frame: Predose, and at designated timepoints up to 144 hours post-dose
  3. Maximum concentration (Cmax) of opevesostatTime frame: Predose, and at designated timepoints up to 144 hours post-dose
  4. Time to Maximum concentration (Tmax) of opevesostatTime frame: Predose, and at designated timepoints up to 144 hours post-dose
  5. Apparent terminal half-life (t1/2) of opevesostatTime frame: Predose, and at designated timepoints up to 144 hours post-dose
  6. Apparent Clearance (CL/F) of opevesostatTime frame: Predose, and at designated timepoints up to 144 hours post-dose
  7. Apparent volume of distribution during terminal phase (Vz/F) of opevesostatTime frame: Predose, and at designated timepoints up to 144 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion, Inc. ( Site 0001)

    Lincoln, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.